Pulmonary Arterial Hypertension Treatment Market to Witness Sales Slump in Near Term Due to COVID-19; Long-term Overview Remains Positive-2022-2028

 Owing to non-responsive nature of several advance pharmacotherapies and high diagnosis and treatment costs, researchers and medical practitioners in the global pulmonary arterial hypertension treatment market are continually working on favorable and effective alternative treatment models and increase survival rate among the patients with pulmonary arterial hypertension.

Future Market Insights, in its recently published outlook on the global market for pulmonary arterial hypertension treatment market, projects the US$ 5 billion market to barely exceed US$ 6.5 billion in terms of revenue, through the next decade.

Get the Sample here: https://www.futuremarketinsights.com/reports/sample/rep-gb-1218

The market has been estimated at a sluggish CAGR of 2.5% over 2022-2028. However, innovations and combination therapeutics are likely to forestall further decline of the pulmonary arterial hypertension treatment market in near future.

Cancer Protein Molecules Tested for Potential Therapeutic Use- to Prevent Pulmonary Arteries ‘Scarring’

Scarring or Fibrosis, in pulmonary arterial hypertension, is an important cause of damage to pulmonary arteries, which in turn, strains the heart functions- eventually leading to breathlessness. Recently, researchers from Brigham and Women's Hospital conducted a study using network medicine- a method of establishing correlation between proteins, pathways and more- and identified the cancer protein NEDD9 and its molecular mechanisms as a potential treatment for PAH patients. The study has identified that a specific amino acid residue in the cancer protein is expected to play a crucial role in controlling and regulating the severe consequences of scarring.

BH4- Factor Controlling Production of Nitric Oxide- Shows Promising Result on Rat Model; Results Show Lower Lung Hypertension

Researchers at Imperial College London and Bar-Ilan University, Israel explored the properties of naturally occurring tetrahydrobiopterin (BH4) and its subsequent role in effective treatment for lung hypertension and right heart failure.

BH4 controls the production of endothelial nitric oxide synthase (eNOS) in the human body. eNOS produces nitric oxide which is important for healthy endothelial cells- forming the inside lining of blood vessels. Nitric oxide is responsible for dilating blood vessels, working to lower lung blood pressure.

The study- conducted on a rats first in injected with chemical triggering pulmonary hypertension and then an injection of BH4, showed signs of decreased lung pressure, stronger heart contractions and, enlarged heart.  The rats were then given BH4 in food before the chemical that previously induced pulmonary hypertension. As a result of which, no thick layers of smooth muscles were developed- often leading to lung hypertension.

After the phase 1 of clinical trials, the patients- administered BH4 orally, showed improved exercise capacity- an indicator of low pressure in lungs. It is anticipated that BH4, when given controlled measure could prove to a valuable treatment for pulmonary arterial hypertension patients who otherwise are not responsive to regular medication.

With Treatment Options, ‘Accurate Risk Measuring’ Tools is the Need of the Hour

Although measurable efforts are being made in the global pulmonary arterial hypertension treatment market, the survival rate among PAH patients continues to remain low.  According to studies, the average life expectancy of PAH patient is approximately 3 years from symptom onset- being at a risk of disease progression and frequent hospitalizations.

Several studies indicate that early diagnosed and ‘low-risk’ patients stand a chance of improved survival if the risk is calculated accurately. Experts have expressed the need to develop appropriate and accurate risk prediction tools improve treatment outcomes in PAH patients.

Increasing prevalence and incidence rate is driving the global pulmonary arterial hypertension treatment market. Advancements are being made for early diagnosis and improved treatment.

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
​United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Comments

Post a Comment

Popular posts from this blog

Dairy Flavored Milk Market: Worldwide Industry Analysis of Key Findings, and New Market Opportunities Explored by 2022-2032

  Dairy Flavored milk  is a product manufactured by mixing milk, sugar or sweetener, coloring, and natural or artificial flavor. Flavored milk offers some essential nutrients like calcium, potassium, vitamins, phosphorus, and protein. Flavored milk is among the healthiest products from the food and beverage industry. Its health benefit is a boost for the market as consumers are moving towards healthy lifestyles. Also, the high shelf life and increase in demand for refrigerated milk products fuel the growth of the flavored milk market globally. The worldwide flavored milk market is supposed to arrive at a valuation of US$ 3,300 Million of every 2022. Generally speaking, deals of flavored milk are projected to develop at a strong CAGR of 6.4% somewhere in the range of 2022 and 2032, adding up to around US$ 6,119.3 Million toward the finish of 2032 The global dairy flavored milk industry is still on the rise as consumption is still low compared to other drinks like carbonated soft dri
Read more

Peanut Butter Market 2022: Increasing Demand for Efficient Management Practices, Key Segment & Opportunities Report-2030

Peanut butter is a low-calorie product with high protein content prepared from grinding of dry roasted peanuts. It serves as a substitute for the dairy butter. Peanut butter can be used as toppings for food products like bread, crackers, and many others. Peanut butter finds application in several end-user sectors such as bakery, savory and sauces, smoothies, and many more. Peanut butter is a rich source of energy that can be used as an alternative to milk butter. Aside the energy derived from the consumption, peanut butter is also a good source of protein, fiber, unsaturated fat and minerals such as magnesium, zinc, potassium, and vitamin E. With these nutritional value obtained from the consumption of peanut butter, the global market is slated to witness robust growth over the forecast period. Moreover, the growing population size of consumers with weight diseases and increasing disposable income of consumers in developed and developing countries are major factors expected to p
Read more

Global Vegan Fast Food Market Current and Future Trends, Growth Insights, Industry Segments and Regional Forecast by 2033

 The global vegan fast food market is predicted to be worth US$ 18829.5 million in 2023 and US$ 27980.2 million by 2033 The global vegan fast food market is predicted to develop due to increased knowledge about the benefits of a vegan diet. An additional factor, such as growing awareness of animal health and cruelty in the food industry, has encouraged individuals to transition from animal-based to plant-based fast food, which has contributed to the market's growth. As a result of these reasons, demand for vegan fast food is expected to rise at a constant 4.5% CAGR, with the United Kingdom, the United States, Germany, and Japan emerging as important manufacturers. Download Comprehensive Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16198 The rise in awareness of health issues and human well-being, as well as changes in lifestyle, are the factors driving the growth of the global vegan fast food market. People are migrating toward vegetarian food
Read more